MAPT and neuroblastoma: Sud et al. (2014) employed morpholino ASOs to target MAPT in the human neuroblastoma cell lines, SH-SY5Y and IMR32, and in tau transgenic mice. These ASOs reduced MAPT mRNA up to 50% and protein up to 80% (Sud et al., 2014). Another study demonstrated the ability of 2′-O-Methyl (2′-O-Me) modified ASOs on a PS backbone to reduce MAPT mRNA (92% reduction) and tau protein (50% reduction after 48-h treatment) levels in vitro in SH-SY5Y cells (Chakravarthy et al., 2020). These studies underscore the capability of ASOs in vitro and in vivo as excellent reagents to lower tau levels.